[go: up one dir, main page]

WO2006091719A3 - Compositions and methods enhancing transdermal delivery of drugs and biologics - Google Patents

Compositions and methods enhancing transdermal delivery of drugs and biologics Download PDF

Info

Publication number
WO2006091719A3
WO2006091719A3 PCT/US2006/006385 US2006006385W WO2006091719A3 WO 2006091719 A3 WO2006091719 A3 WO 2006091719A3 US 2006006385 W US2006006385 W US 2006006385W WO 2006091719 A3 WO2006091719 A3 WO 2006091719A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
skin
permeation
drug
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/006385
Other languages
French (fr)
Other versions
WO2006091719A2 (en
Inventor
Shikha P Barman
Hannah Farnham
Lauren K Roode
Anna Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sontra Medical Corp
Original Assignee
Sontra Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sontra Medical Corp filed Critical Sontra Medical Corp
Publication of WO2006091719A2 publication Critical patent/WO2006091719A2/en
Publication of WO2006091719A3 publication Critical patent/WO2006091719A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Improved methods for transdermal transport of drug formulations are described herein. Formulations designed to enhance transport of therapeutic levels of topically applied drugs into the systemic circulation, methods of making the formulations are also described herein. The formulations contain at least one active agent to be delivered and at least one skin permeation enhancer in a polymeric hydrogel, and optional additional excipients. Methods for enhancing transport of formulations into and through the skin include: (a) pretreatment of the skin with a hydrating solution, (b) physical permeation of the stratum corneum by low frequency ultrasound (administered by a sono-permeation device, such as SONOPREP®, available from Sontra Medical Corporation, Franklin, MA), (c) topical application of a formulation containing the bioactive molecule, and optionally (d) application of an electric potential difference that forces ionized drugs through the skin. Optionally, the formulation contains permeation-enhancing agents. The method may be used with the formulations described herein or with other formulations for topical administration. In a preferred embodiment, the active agent to be delivered is a drug. Preferably the drug is a local anesthetic, such as lidocaine.
PCT/US2006/006385 2005-02-23 2006-02-23 Compositions and methods enhancing transdermal delivery of drugs and biologics Ceased WO2006091719A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65534805P 2005-02-23 2005-02-23
US60/655,348 2005-02-23

Publications (2)

Publication Number Publication Date
WO2006091719A2 WO2006091719A2 (en) 2006-08-31
WO2006091719A3 true WO2006091719A3 (en) 2007-05-18

Family

ID=36927999

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/006385 Ceased WO2006091719A2 (en) 2005-02-23 2006-02-23 Compositions and methods enhancing transdermal delivery of drugs and biologics

Country Status (1)

Country Link
WO (1) WO2006091719A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0700832B8 (en) * 2007-03-16 2021-05-25 Biolab Sanus Farmaceutica Ltda topical anesthetic composition comprising suspension of polymeric nanocapsules of lidocaine and prilocaine
US8609733B2 (en) 2008-05-19 2013-12-17 Massachusetts Institute Of Technology Sensory-specific local anesthesia and prolonged duration local anesthesia
BRPI0913809B1 (en) 2008-10-02 2019-02-05 Mylan Inc method for continuously producing a multilayer pressure sensitive adhesive laminate
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
SG175327A1 (en) * 2009-04-22 2011-11-28 Agency Science Tech & Res Emulsions for transdermal delivery
AU2014232881B2 (en) 2013-03-15 2017-04-27 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia
DE102020200423A1 (en) * 2020-01-15 2021-07-15 Beiersdorf Aktiengesellschaft Method for the introduction of active substances into the skin
US12440427B2 (en) * 2022-08-05 2025-10-14 Denis Simioni Skin dough composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939485A (en) * 1995-06-19 1999-08-17 Medlogic Global Corporation Responsive polymer networks and methods of their use
WO2000018339A1 (en) * 1998-09-29 2000-04-06 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US6503955B1 (en) * 1999-09-11 2003-01-07 The Procter & Gamble Company Pourable liquid vehicles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939485A (en) * 1995-06-19 1999-08-17 Medlogic Global Corporation Responsive polymer networks and methods of their use
WO2000018339A1 (en) * 1998-09-29 2000-04-06 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US6503955B1 (en) * 1999-09-11 2003-01-07 The Procter & Gamble Company Pourable liquid vehicles

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
EL-KATTAN AYMAN F ET AL: "The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities", INTERNATIONAL JOURNAL OF PHARMACEUTICS (KIDLINGTON), vol. 215, no. 1-2, 14 March 2001 (2001-03-14), pages 229 - 240, XP002415838, ISSN: 0378-5173 *
ESCOBAR-CHÁVEZ JOSÉ JUAN ET AL: "In vivo skin permeation of sodium naproxen formulated in pluronic F-127 gels: effect of Azone and Transcutol.", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY MAY 2005, vol. 31, no. 4-5, May 2005 (2005-05-01), pages 447 - 454, XP009077487, ISSN: 0363-9045 *
FANG JIA-YOU ET AL: "Transdermal iontophoresis of sodium nonivamide acetate V. Combined effect of physical enhancement methods", INTERNATIONAL JOURNAL OF PHARMACEUTICS (KIDLINGTON), vol. 235, no. 1-2, 20 March 2002 (2002-03-20), pages 95 - 105, XP002415857, ISSN: 0378-5173 *
LIAW J ET AL: "Evaluation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) gels as a release vehicle for percutaneous fentanyl", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 68, no. 2, 10 August 2000 (2000-08-10), pages 273 - 282, XP004228957, ISSN: 0168-3659 *
MURA P ET AL: "Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 9, no. 4, February 2000 (2000-02-01), pages 365 - 372, XP002315954, ISSN: 0928-0987 *
PILLAI O ET AL: "Transdermal delivery of insulin from poloxamer gel: ex vivo and in vivo skin permeation studies in rat using iontophoresis and chemical enhancers", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 89, no. 1, 14 April 2003 (2003-04-14), pages 127 - 140, XP004420215, ISSN: 0168-3659 *
SHIM J ET AL: "Transdermal delivery of mixnoxidil with block copolymer nanoparticles", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 97, no. 3, 7 July 2004 (2004-07-07), pages 477 - 484, XP004519511, ISSN: 0168-3659 *
SHIN SANG-CHUL ET AL: "Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins", INTERNATIONAL JOURNAL OF PHARMACEUTICS (KIDLINGTON), vol. 222, no. 2, 17 July 2001 (2001-07-17), pages 199 - 203, XP002415837, ISSN: 0378-5173 *

Also Published As

Publication number Publication date
WO2006091719A2 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
Priya et al. Transdermal iontophoresis
EA200301200A1 (en) THE COMPOSITION OF A SELECTIVE INHIBITOR CYCLOOXIGENASE-2, penetrating through the skin
US20080008745A1 (en) Transdermal delivery of naltrexone hydrochloride, naltrexol hydrochloride, and bis(hydroxy-methyl)propionyl-3-0 ester naltrexone using microneedles
EP3721893B1 (en) Treatment of erectile dysfunction
EP2872177B1 (en) Diclofenac formulations
US20140004176A1 (en) Delivery of treatments transdermally for fungal infections and other indications
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
EP2246049A3 (en) Pharmaceutical composition and dosage forms for administration of hydrophobic drugs
EP0857488A3 (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers
EP0857488A1 (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers
BRPI0508933A (en) compositions for topical delivery
BRPI0406911A (en) Pharmaceutical and / or cosmetic product
WO2010034019A4 (en) Transdermal drug delivery using an osmolyte and vasoactive agent
US9289495B2 (en) Systems and methods for treatment of allergies and other indications
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
US20040131665A1 (en) Topical anesthetic formulation
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
KR20140074881A (en) Alcaftadine for use in the treatment of urticaria
US20200301526A1 (en) Novel non-aqueous topical solution of diclofenac and process for preparing the same
DK1280558T3 (en) Semi-solid administration vehicle and pharmaceutical compositions
WO2006091719A3 (en) Compositions and methods enhancing transdermal delivery of drugs and biologics
Stahl et al. The effects of chemical and physical penetration enhancers on the percutaneous permeation of lidocaine through equine skin
ES2982022T3 (en) Topical formulations of detomidine
EP1968541A2 (en) Compositions and methods for dermal delivery of drugs
Mathews et al. Management of pain using transdermal patches-a review

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06735872

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06735872

Country of ref document: EP

Kind code of ref document: A2